Background {#Sec1}
==========

Prostate cancer (PCA) is the second most frequent tumor in men worldwide, with 1.27 million new cases and 0.35 million deaths in 2018 \[[@CR1], [@CR2]\]. The incidence and mortality of PCA are correlated with increasing age, and the average age at the time of diagnosis is over 66 years in some regions. Additionally, there is also evidence of an association between ethnicity and PCA; for example, the incidence rate in African-American men is 158.3 newly diagnosed cases/100,000, which is higher than that in White men, and their mortality is about twice that of White men according to Panigrahi et al. \[[@CR3]\]. Several factors may contribute to this disparity, such as differences in diet, habits/customs, and genetic/environmental factors.

There is growing evidence that chronic inflammation is involved in the regulation of cellular events in prostate carcinogenesis, including disruption of the immune response and regulation of the tumor microenvironment \[[@CR4]\]. One of the best surrogates of chronic inflammation in PCA is the cytokine tumor necrosis factor alpha (TNF-α) \[[@CR5], [@CR6]\]. Chadha et al. indicated the median TNF-α levels in serum was significantly higher (*P* \< 0.05) in the control group (5.12 pg/ml) than in the localized PCA group (2.20 pg/ml). Moreover, TNF-α was the strongest single predictor between localized and metastatic PCA (Area Under Curve, AUC = 0.992) and was higher than the PSA value (AUC = 0.963). Taken together, these results suggest that TNF-α may be considered a novel serum biomarker for the diagnosis of PCA \[[@CR7]\].

The TNF-α gene, also termed DIF/TNFSF2/TNLG1F, is located in the class III region of the major histocompatibility complex (MHC III) and mapped to chromosome 6p21.33 with 4 exons \[[@CR8], [@CR9]\]. Several single nucleotide polymorphisms (SNPs) in this gene have been widely reported and have been associated with the risk of several cancers, such as PCA, breast cancer, and lung cancer \[[@CR10]--[@CR12]\]. Rs1800629 is one of the most common SNPs, with a G to A transition at the − 308 nucleotide in the promoter of the transcription initiation site, which may affect the serum expression of TNF-α \[[@CR13]\]. Another common SNP named rs361525 is located at the − 238 site, where a G to A substitution is shown, and may influence TNF-α in the serum \[[@CR14]\]. The rs1799724 (C to T transition) and rs1799964 (T to C transition) SNPs have been reported in recent years \[[@CR15], [@CR16]\]; however, to date, it is not known whether these two SNPs can affect the expression of TNF-α.

Previously, two meta-analyses focused on TNF-α polymorphisms and PCA risk have been published: Cai et al. identified 12 case-control studies and concluded that the rs1800629 polymorphism had an increased association with PCA risk in the GA vs. GG genetic model (OR = 1.19, 95% CI = 1.04--1.37) \[[@CR17]\]. Ma et al., however, suggested that the rs361525 polymorphism was not associated with PCA, and the rs1800629 polymorphism, which is also the susceptible SNP for PCA, only had a significant association in healthy volunteers (AG vs. GG: OR = 1.47, 95% CI = 1.04--2.08) \[[@CR18]\]. Due to these inconclusive results, as well as the publication of some additional studies, it was necessary to re-combine all of the articles, including 22 different case-control studies \[[@CR15], [@CR16], [@CR19]--[@CR36]\], to conduct an updated meta-analysis.

Methods {#Sec2}
=======

Literature search and inclusion criteria {#Sec3}
----------------------------------------

We performed a literature search for all eligible articles regarding the association between four TNF-α polymorphisms and PCA risk on multiple electronic databases, including PubMed, Embase, Wanfang and CNKI, using the following keywords: 'tumor necrosis factor alpha OR TNF-α' AND 'polymorphism OR variation OR mutation' AND 'prostate cancer OR carcinoma OR neoplasm OR tumor' until Nov 15, 2019.

Relevant studies were selected based on the following inclusion criteria: (1) case-control studies addressing the correlation between a TNF-α polymorphism and PCA risk; (2) studies containing sufficient genotype data on both the cases and controls; and (3) the largest sample sizes were selected among articles with overlapping study groups. The exclusion criteria were (1) conference abstracts, case reports, reviews and duplicated information; and (2) inadequate genotype data.

Data extraction {#Sec4}
---------------

The following data were gathered from each eligible study: the first author's name, publication year, country, sample size for the case and control groups, source of control, Hardy-Weinberg equilibrium (HWE) of the controls, genotyping techniques and the genotype of the cases and controls.

Statistical analysis {#Sec5}
--------------------

The strength of the association between the four TNF-α polymorphisms and PCA susceptibility was measured by the odds ratio (OR) with 95% confidence interval (CI) in 3 (allele, heterozygous and dominant) genetic models. The significance of the pooled OR was assessed by the *Z*-test, and *P* \< 0.05 was considered to be statistically significant. The between-study heterogeneity was evaluated by the *Q*-test. In cases where significant heterogeneity was detected, if *P* \< 0.1, indicating the presence of heterogeneity, a random-effects model was selected; otherwise, a fixed-effects model was applied \[[@CR37], [@CR38]\]. Publication bias was inspected using Begg's test, and Egger's test was used to measure the degree of asymmetry. In both tests, *P* \< 0.05 was considered statistically significant \[[@CR39]\]. The HWE of the control group was specified through the chi-square test, where *P* \< 0.05 was considered significant \[[@CR40]\]. Sensitivity analyses were done to evaluate whether a single study influenced the overall pooled results by omitting each study in turn. All statistical tests used in this study were performed using Stata (version 11.0; StataCorp LP, College Station, TX).

Results {#Sec6}
=======

Characteristics of selected studies {#Sec7}
-----------------------------------

A total of 168 published articles were retrieved from the PubMed, Embase, Wanfang and CNKI databases in accordance with the selection criteria. Finally, 20 different articles (22 case-control studies) were included in our meta-analysis (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}) \[[@CR15], [@CR16], [@CR19]--[@CR36]\]. Of the 22 studies, TNF-α rs1800629 was analyzed in 22 studies; rs361525, in 8 studies; rs1799724, in 5 studies; and rs1799964, in 3 studies. Only three available reports investigated rs1799964 and PCA susceptibility, so we did not analyze this association. Table [1](#Tab1){ref-type="table"} shows the features and related information of the included studies. In addition, we checked the Minor Allele Frequency (MAF) reported for the five main worldwide populations in the 1000 Genomes Browser for each SNP: East Asian (EAS), European (EUR), African (AFR), American (AMR), and South Asian (SAS) (Fig. [2](#Fig2){ref-type="fig"}). Table 1Characteristics of the studies eligible for current meta-analysisAuthorYearCountryEthnicityCaseControlSOCCasesControlsHWEGenotypeMMMWWWMMMWWWrs1800629 Jones2013USAAfrican-American279535HB5103171141533680.687Illumina's Golden gate Zabaleta2008USAAfrican-American67130HB2956333940.958Sequence Berhane2012IndiaAsian150150HB6241201181310.662ARMS-PCR Wu2003China-TaiwanAsian96126HB220741221030.882PCR-RFLP Alidoost2019IranAsian100110HB01684014960.476PCR-RFLP/ARMS-PCR Kesarwani2009IndiaAsian197256HB1211754372150.115PCR-RFLP Ali2019IraqAsian3030PB1218024600.543PCR-RFLP Ge2007ChinaAsian245245HB2392042481950.609TaqMan Dluzniewski2012USACaucasian468468HB1411334161263360.125MassArray Pardo2019VenezuelaCaucasian4040HB0634011290.313PCR-RFLP Zabaleta2008USACaucasian479400HB9148322101182720.505Sequence Sáenz-López2008SpainCaucasian296310PB5702212522560.714TaqMan Moore2009USACaucasian949857PB21228700112056410.231TaqMan Danforth2008USACaucasian11551380PB26336793454189260.795TaqMan/MGBEclipse assay Danforth2008USACaucasian11111125PB25294792332868060.217TaqMan/MGBEclipse assay Ribeiro2012PortugalCaucasian449557PB811532671434070.155TaqMan Wang2009USACaucasian251250PB12791609691720.529TaqMan Bandil2017IndiaAsian105115HB9158147104\< 0.001ARMS-PCR Omrani2008IranAsian41105HB03653993\< 0.001ASO-PCR McCarron2002United KingdomCaucasian239220HB66616713571500.023ARMS-PCR OH2000USACaucasian7373HB0532005320\< 0.001allele-specific PCR Zhang2010USACaucasian116128PB116128CBMALD-TOF-MSrs361525 Pardo2019VenezuelaCaucasian4040HB043601390.936PCR-RFLP OH2000USACaucasian7373HB02350023500.11allele-specific PCR Zabaleta2008USACaucasian471385HB6414240393460.295Sequence Alidoost2019IranAsian100110HB01090051050.807PCR-RFLP/ARMS-PCR Danforth2008USACaucasian11141126PB1121992310010230.737TaqMan/MGBEclipse assay Ge2007ChinaAsian245245HB0102350222230.461TaqMan Zabaleta2008USAAfrican-American64126HB06582101140.006Sequence Bandil2017IndiaAsian105115HB12603320869\< 0.001ARMS-PCRrs1799724 Danforth2008USACaucasian11391378PB132039231425411100.9TaqMan/MGBEclipse assay Danforth2008USACaucasian11081101PB17183908192208620.257TaqMan/MGBEclipse assay Kesarwani2009IndiaAsian197256HB4571364561961PCR-RFLP Zabaleta2008USAAfrican-American464372HB659399841323\< 0.001Sequence Zabaleta2008USACaucasian614HB303707\< 0.001Sequencers1799964 Danforth2008USACaucasian11421375PB60361721584418760.791TaqMan/MGBEclipse assay Danforth2008USACaucasian11431155PB54370719643777140.129TaqMan/MGBEclipse assay Kesarwani2009IndiaAsian197256HB906443839182\< 0.001PCR-RFLP*HB* hospital-based, *PB* population-based, *SOC* source of control, *PCR-FLIP* polymerase chain reaction and restrictive fragment length polymorphism; *ARMS* amplification refractory mutation system, *HWE* Hardy--Weinberg equilibrium of control group, *W* wild type-allele, *M* mutant-alleleFig. 1A flowchart illustrating the search strategy about TNF-α rs1800629, rs361525, rs1799724 and rs1799964 polymorphisms and PCA risk was shownFig. 2MAF for the TNF-α rs1800629, rs361525 and rs1799724 polymorphsms from 1000 Genomes Browser. Vertical line, MAF; Horizontal line, ethnicity type. EAS: East Asian; EUR: European; AFR: African; AMR: American; SAS: South Asian

Pooled analysis results {#Sec8}
-----------------------

Overall, the findings did not support an association between the TNF-α rs1800629 polymorphism and PCA susceptibility in the allele (OR = 1.03, 95% CI = 0.92--1.16, *P* = 0.580, Fig. [3](#Fig3){ref-type="fig"}a), heterozygous (OR = 1.04, 95% CI = 0.93--1.17, *P* = 0.486) and dominant (OR = 1.06, 95% CI = 0.94--1.18, *P* = 0.353) genetic models. To evaluate the power and stability, some studies not consistent with HWE were excluded, and similar results were obtained. Stratified analyses by ethnicity, source of control and genotyping methods were conducted, and no significant association was detected (Table [3](#Tab3){ref-type="table"}). Fig. 3Meta-analysis. **a**. Forest plots of TNF-α rs1800629 polymorphism and PCA risk (A-allele vs. G-allele). **b**. Forest plot of TNF-α rs1799724 polymorphism and PCA risk (T-allele vs. C-allele). **c**. Forest plot of TNF-α rs361525 polymorphism and PCA risk (AA vs. GG). **d**. Forest plot of TNF-α rs361525 polymorphism and PCA risk (A-allele vs. G-allele) on subgroup of genotyping method (Others). **e**. Forest plot of TNF-α rs361525 polymorphism and PCA risk (A-allele vs. G-allele) on subgroup of genotyping method (PCR-RFLP)

For the TNF-α rs1799724 polymorphisms, no significant associations were identified in the cases and subgroups. Further, the rs1799724 polymorphism was not significantly associated with PCA in the allele (OR = 0.95, 95% CI = 0.84--1.07, *P* = 0.381, Fig. [3](#Fig3){ref-type="fig"}b), heterozygous (OR = 1.01, 95% CI = 0.80--1.27, *P* = 0.951) and dominant genetic models (OR = 0.95, 95% CI = 0.83--1.07, *P* = 0.390).

For the TNF-α rs361525 polymorphism, although no association was found in the allele (OR = 0.93, 95% CI = 0.66--1.32, *P* = 0.684), heterozygous (OR = 0.86, 95% CI = 0.52--1.41, *P* = 0.542, Fig. [3](#Fig3){ref-type="fig"}c) and dominant models (OR = 0.85, 95% CI = 0.52--1.39, *P* = 0.525), for HWE, ethnicity and source of control, pooled significant relationships were observed in genotyping subgroups, such as Others (OR = 0.65, 95% CI = 0.47--0.89, *P* = 0.008 for A-allele vs. G-allele, Fig. [3](#Fig3){ref-type="fig"}d) and PCR-RFLP (OR = 2.68, 95% CI = 1.00--7.20, *P* = 0.050, Fig. [3](#Fig3){ref-type="fig"}e).

Heterogen {#Sec9}
---------

### Heterogeneity and publication bias {#Sec10}

As shown in Table [2](#Tab2){ref-type="table"}, heterogeneity among the studies was found in all three genetic comparisons for all 3 SNPs (rs1800629, rs361525 and rs1799724). Table 2The pooled ORs and 95%CIs for the association between TNF polymorphisms and prostate cancer susceptibility in total and stratified analysisVariablesNCase/ControlM-allele vs. W-allele\
OR(95%CI) *P*~h~*P*MW vs. WW\
OR(95%CI) *P*~h~*P*MM + MW vs. WW\
OR(95%CI) *P*~h~*P*rs1800629 Total226936/76191.03 (0.92--1.16)0.001 0.5801.04 (0.93--1.17)0.040 0.4861.06 (0.94--1.18)0.013 0.353 HWE187485/67921.03 (0,92--1.16)0.006 0.5841.04 (0,93--1.16)0.091 0.5091.05 (0,94--1.17)0.051 0.429Ethnicity Asian8964/11371.03 (0.68--1.56)0.000 0.8811.04 (0.70--1.56)0.038 0.8451.09 (0.70--1.71)0.006 0.698 Caucasian125626/58171.01 (0.94--1.08)0.223 0.8381.02 (0.94--1.11)0.525 0.6721.02 (0.94--1.11)0.433 0.625 African-American2346/6650.93 (0.47--1.86)0.049 0.8430.87 (0.28--2.67)0.009 0.8040.90 (0.34--2.37)0.016 0.829SOC HB142579/29731.02 (0.86--1.22)0.012 0.7871.00 (0.81--1.22)0.023 0.9721.01 (0.82--1.24)0.012 0.787 PB84357/46461.04 (0.89--1.22)0.009 0.6001.04 (0.94--1.14)0.298 0.4831.04 (0.95--1.14)0.199 0.425Genotyping Others5977/13091.07 (0.91--1.26)0.420 0.4200.97 (0.62--1.53)0.021 0.9001.07 (0.79--1.45)0.079 0.668 Sequencing2546/5300.94 (0.75--1.19)0.166 0.6080.76 (0.34--1.70)0.055 0.5050.80 (0.41--1.55)0.086 0.506 TaqMan74456/47331.04 (0.92--1.17)0.081 0.5201.02 (0.93--1.12)0.278 0.6381.02 (0.93--1.12)0.152 0.672 PCR-RFLP5463/5620.74 (0.43--1.28)0.030 0.2800.90 (0.63--1.29)0.263 0.5650.89 (0.63--1.26)0.186 0.520 ARMS-PCR3494/4851.56 (0.74--3.29)0.001 0.2391.28 (0.93--1.78)0.163 0.1351.54 (0.80--2.97)0.024 0.192rs361525 Total82212/22220.93 (0.66--1.32)0.007 0.6840.86 (0.52--1.41)0.000 0.5420.85 (0.52--1.39)0.000 0.525 HWE62043/19791.11 (0,91--1.35)0.111 0.3211.02 (0,69--1.52)0.055 0.9051.05 (0,73--1.52)0.803 0.794Ethnicity Asian3450/4700.72 (0.34--1.50)0.039 0.3800.55 (0.15--1.99)0.002 0.3600.54 (0.15--2.00)0.001 0.357 Caucasian41698/16241.16 (0.94--1.44)0.673 0.1641.16 (0.94--1.44)0.673 0.1641.16 (0.94--1.44)0.673 0.164 African-American164/126------Genotyping Others2178/1880.65 (0.47--0.89)0.111 0.0080.44 (0.09--2.25)0.002 0.3260.44 (0.08--2.28)0.002 0.325 Sequencing2535/5111.07 (0.72--1.57)0.595 0.7460.90 (0.59--1.38)0.590 0.6330.98 (0.65--1.48)0.999 0.936 PCR-RFLP2140/1502.59 (0.98--6.85)0.628 0.0552.68 (1.00--7.20)0.626 0.0502.68 (1.00--7.20)0.626 0.050 TaqMan21359/13710.77 (0.30--2.01)0.017 0.5990.78 (0.28--2.20)0.011 0.6400.77 (0.28--2.13)0.013 0.620rs1799724 Total52914/31210.95 (0.84--1.07)0.169 0.3811.01 (0.80--1.27)0.054 0.9510.95 (0.83--1.07)0.120 0.390 HWE32444/27350.99 (0,78--1.26)0.042 0.9300.98 (0,74--1.30)0.037 0.8960.99 (0,75--1.30)0.032 0.931 Caucasian32253/24930.90 (0.79--1.03)0.403 0.1150.88 (0.76--1.02)0.196 0.0820.88 (0.76--1.02)0.400 0.089*P*~h~: value of *Q*-test for heterogeneity test; *P*: *Z*-test for the statistical significance of the OR; *HB* hospital-based, *PB* population-based, *SOC* source of control, *PCR-FLIP* polymerase chain reaction and restrictive fragment length polymorphism, *ARMS* amplification refractory mutation system *HWE*, Hardy--Weinberg equilibrium of control group, *W* wild type-allele, *M* mutant-allele

The publication bias was assessed by applying Begg's funnel plot and Egger's test. Based on the samples and publications, we tested two SNPs, rs1800629 and rs361525. The shape of the funnel plots was symmetrical, and the Egger's test supported no existence of publication bias in any of the three comparisons for the rs1800629 (*t* = 0.01, *p* = 0.989 for Egger's test; *z* = 0.21, *p* = 0.833 for Begg's test, Fig. [4](#Fig4){ref-type="fig"}a, b) and rs361525 (*t* = − 0.3, *p* = 0.765 for Egger's test; z = − 0.12, *p* = 1 for Begg's test, Fig. [4](#Fig4){ref-type="fig"}c, d) polymorphisms (Table [3](#Tab3){ref-type="table"}). Fig. 4Publication bias. **a**. Begg's funnel plot for publication bias test (A-allele vs. G-allele). **b**. Egger's publication bias plot (A-allele vs. G-allele). **c**. Begg's funnel plot for publication bias test (A-allele vs. G-allele). **d**. Egger's publication bias plot (A-allele vs. G-allele)Table 3Publication bias tests (Begg's funnel plot and Egger's test for publication bias test) for rs1800629 and rs361525 polymorphismsEgger's testBegg's testGenetic typeCoefficientStandard error*tP* value95%CI of intercept*zP* valuers1800629 A-allele vs. G-allele0.0090.6810.010.989(−1.418--1.437)0.210.833 AG vs. GG0.3310.5280.630.539(−0.779--1.440)0.10.922 AA+AG vs. GG0.0460.6190.070.941(−1.249--1.341)0.330.74rs361525 A-allele vs. G-allele−0.2161.2590.170.87(−2.866--3.297)0.120.902 AG vs. GG−0.2930.935−0.30.765(−2.582--1.996)− 0.121 AA+AG vs. GG−0.3030.938−0.30.757(−2.599--1.991)− 0.121

Sensitivity analysis {#Sec11}
--------------------

We performed sensitivity analyses to assess the effect of a specific publication on the overall estimate. Similar with publication bias, we also analyzed both rs1800629 and rs361525 (Fig. [5](#Fig5){ref-type="fig"}a, b), and no significant changes were observed when excluding each study in any of the three genetic models (allele, heterozygous and dominant). Thus, the final pooled results are both stable and reliable. Fig. 5Sensitivity analysis. **a**. Sensitivity analysis for TNF-α rs1800629 polymorphism and RA risk (A-allele vs. G-allele). **b**. Sensitivity analysis between TNF-α rs361525 polymorphism and RA risk (A-allele vs. G-allele)

Discussion {#Sec12}
==========

There is evidence to suggest that chronic inflammation is prevalent in the adult prostate and may contribute to disease development in the form of promoting tumor initiation and progression \[[@CR5], [@CR41]\]. Therefore, chronic inflammation has been considered an enabling characteristic in the development of cancers \[[@CR42]\], such as PCA. Several previous epidemiological studies have been explored to make a connection between inflammation and PCA development, showing evidence that associates symptomatic prostatitis with PCA risk \[[@CR43]--[@CR45]\]. For example, men with prostatitis have increased serum PSA levels, and while a medical diagnosis for prostatitis symptoms may be received initially, they may be screened for PCA and might be diagnosed with PCA in the end. Furthermore, many men with prostatic inflammation without symptoms also have increased PSA values, which may increase the odds of visits to the doctor, and they may be identified as having PCA \[[@CR45]\]. Taken together, these observations indicate that the detection of inflammation in the prostate may be helpful for us to better identify PCA patients; however, there are no specific biomarkers of prostate inflammation to date.

Studying both pro- and anti-inflammatory cytokine genes is essential for PCA \[[@CR21]\]. TNF-α, as a main mediator of inflammation, has a vital role in PCA development \[[@CR10]\]. By considering the capacity of TNF-α promoter SNPs (rs1800629 and rs361525), and the influence of their gene expression \[[@CR13], [@CR14]\], these two SNPs have been identified as potential functional variants and as novel biomarkers for the early detection for PCA susceptibility.

Several studies and two meta-analyses have examined the association between TNF-α gene polymorphisms and PCA risk \[[@CR15]--[@CR36]\]. Nevertheless, the findings were inconsistent, possibly due to the small samples or relatively low statistical power of the included studies. Therefore, a current, updated meta-analysis with a comprehensive assessment that included more eligible studies was performed to evaluate the impact of TNF-α gene polymorphisms (rs1800629, rs361525 and rs1799724) on PCA susceptibility, which may overcome the aforementioned disadvantages \[[@CR15], [@CR16], [@CR19]--[@CR36]\]. For the TNF-α rs1800629 polymorphism, the findings from 20 studies, including 6936 cases and 7619 controls, did not support an association between this variant and PCA risk \[[@CR15], [@CR16], [@CR19]--[@CR36]\]. To the best of our knowledge, for the rs1799724 \[[@CR15], [@CR16], [@CR35]\] polymorphism, which was analyzed for the first time, no significant association was detected from 3 studies, which included 2914 cases and 3121 controls. For the rs361525 polymorphism \[[@CR15], [@CR20], [@CR21], [@CR24], [@CR28], [@CR30], [@CR35]\], pooled significant relationships were observed in the genotyping method subgroups. Cumulatively, we believe no association exists between the four common TNF-α polymorphisms and PCA risk based on the current evidence.

Despite a comprehensive analysis of the current associations between the four TNF-α polymorphisms and the risk of developing PCA, there are some limitations that should be considered. First, the number of samples remains insufficient, especially for the rs1799724 and rs1799964 polymorphisms and ethnicities in some polymorphisms, such as African-American, Asian, African and mixed populations, which perhaps leads to imbalance and publication bias. Second, gene-gene, SNP-SNP and gene-environment interactions should be taken into consideration. Other covariates, including prostate health index, age, family history, environmental factors, Gleason score, TNM stage and living habits, should be better observed, which will help us to draw an exact conclusion. Third, the protein expression level of TNF-α in different polymorphisms should also be observed and be reevaluated by meta-analysis in the future research.

In summary, our study presents evidence that three of the most common TNF-α polymorphisms (rs1800629, rs361525 and rs1799724) are not associated with PCA risk, which should be verified in the future, but they may be poised to become serum biomarkers in several subgroups for the detection of PCA susceptibility.
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